Immutep jumps 24% on positive trial data
Key points
- Immutep reported that its antibody drug IMP761 safely reduced immune responses in a first-in-human trial.
- Company shares surged 23.81% following the release of the trial results.
- Immutep plans to release further ascending-dose data in the new year to set Phase 2 doses.
Biotechnology developer Immutep (ASX:IMM) reported positive trial data showing that its experimental drug IMP761 safely suppressed immune reactions across seven dose levels ranging from 0.03 mg/kg to 14 mg/kg.
The readout builds on earlier findings presented at the European Alliance of Associations for Rheumatology congress, confirming that a single infusion delivered statistically significant, exposure-dependent immune suppression in healthy volunteers.
“These results derived from a large double-blinded trial clearly show the immunosuppressive effect of IMP761 on a strong antigen-driven T-cell response in tissues, without safety concerns,” said Immutep Chief Scientific Officer Dr. Frédéric Triebel.
The trial evaluated healthy participants challenged with keyhole limpet haemocyanin to assess how effectively the therapy blunts tissue-level T-cell responses without generating severe side effects.
Following the announcement, the Immutep share price was up 23.81% at $0.026.
The company stated that IMP761 is currently the only lymphocyte activation gene-3 agonist antibody advancing through clinical development for autoimmune conditions.
Immutep expects to report additional multiple ascending dose results in the new year to guide dose selection for an upcoming Phase 2 trial program.
